Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Cotch, M. F.
space
  arrow  Hoffman, G. S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

HLA Typing in Patients with Wegener Granulomatosis

right arrow Mary Frances Cotch; Anthony S. Fauci; and Gary S. Hoffman

15 April 1995 | Volume 122 Issue 8 | Page 635


TO THE EDITOR:

To investigate a potential genetic basis for Wegener granulomatosis, we screened 83 patients for human leukocyte antigen (HLA) A, B, and C, and DR-DQ markers and compared the frequencies of these phenotypes with those in 4039 normal persons screened for organ donation and 2163 normal persons randomly selected for histocompatibility testing. The results of chi-square analyses showed that B50 and DR9 phenotypes were statistically more likely to occur in patients with Wegener granulomatosis. In the two control groups, the frequency for the B50 phenotype was 1.5% and 2.2%, respectively, and the frequency for the DR9 phenotype was 1.7% and 1.6%, respectively (Table 1). The B50 and DR9 phenotypes, however, occurred in only 8.4% and 6.7% of patients, respectively.


View this table:
[in this window]
[in a new window]
 
Table 1. Frequency of the B50 and DR9 Phenotypes

 

Other authors [1-4] have noted numerous different associations of particular HLA phenotypes in patients with Wegener granulomatosis. Our results, derived from a large series of patients, do not corroborate these findings. If a genetic predisposition exists for developing Wegener granulomatosis, it is not apparent from our analyses. However, other genetic markers may be important in the expression of this disease.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Research Triangle Institute, Center for Medical, Environmental and Energy, Rockville, MD 20852. National Institutes of Health, Bethesda, MD 20892. The Cleveland Clinic Foundation, Cleveland, OH 44195.


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Strimlan CV, Taswell HF, Kueppen F, DeRemee RA, McDonald TJ. HLA antigens of patients with Wegener's granulomatosis. Tissue Antigens. 1978; 11:129-31.

2. Beigel A, Lehmann H, Westphal E. The spectrum of histocompatibility antigens (HLA) in Wegener's granulomatosis. Arch Otolaryngol. 1980; 233:157-60.

3. Elkon KB, Sutherland DC, Rees AJ, Hughes GR, Batchelor JR. HLA antigen frequencies in systemic vasculitis: increase in HLA-DR2 in Wegener's granulomatosis. Arthritis Rheum. 1983; 26:102-5.

4. Papiha SS, Murty GE, Ad'Hiah AH, Mains BT, Venning M. Association of Wegener's granulomatosis with HLA antigens and other geneticmarkers. Ann Rheum Dis. 1992; 51:246-8.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.




This article has been cited by other articles:


Home page
CJASNHome page
R. A.F. de Lind van Wijngaarden, L. van Rijn, E. C. Hagen, R. A. Watts, G. Gregorini, J. W. C. Tervaert, A. D. Mahr, J. L. Niles, E. de Heer, J. A. Bruijn, et al.
Hypotheses on the Etiology of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis: The Cause Is Hidden, but the Result Is Known
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 237 - 252.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. von Vietinghoff, A. Busjahn, C. Schonemann, G. Massenkeil, B. Otto, F. C. Luft, and R. Kettritz
Major Histocompatibility Complex HLA Region Largely Explains the Genetic Variance Exercised on Neutrophil Membrane Proteinase 3 Expression
J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3185 - 3191.
[Abstract] [Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Cotch, M. F.
space
  arrow  Hoffman, G. S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online